tetano
Editor, Senior Moderator
SAGE Open Med Case Rep
. 2022 Jan 11;10:2050313X211069023.
doi: 10.1177/2050313X211069023. eCollection 2022.
Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia
Ramzan Judge[SUP] 1 [/SUP], Stephanie Kolaski[SUP] 2 [/SUP], Farhan Qadeer[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) has affected over 200 million patients worldwide. COVID-19 is transmitted through respiratory droplets from patient to patient or by touching a surface that has been contaminated by an infected patient. Many COVID-19 patients have other comorbidities, such as end-stage renal disease. Currently, management of COVID-19 in patients with end-stage renal disease is unclear. Some studies have shown improvement in this population with the use of tocilizumab, a humanized interleukin-6 monoclonal antibody, in addition to the standard therapy as per guidelines published by the National Institutes of Health. In this case report, we present a patient case where the use of remdesivir, tocilizumab, and pulse-dose methylprednisolone significantly improved symptoms and inflammatory biomarkers associated with COVID-19 in a patient with end-stage renal disease.
Keywords: COVID-19; Critical care/emergency medicine; end-stage renal disease; infectious diseases; nephrology; remdesivir; steroids; tocilizumab.
. 2022 Jan 11;10:2050313X211069023.
doi: 10.1177/2050313X211069023. eCollection 2022.
Use of tocilizumab, remdesivir, and high-dose methylprednisolone prevents intubation in an ESRD patient with COVID-19 pneumonia
Ramzan Judge[SUP] 1 [/SUP], Stephanie Kolaski[SUP] 2 [/SUP], Farhan Qadeer[SUP] 1 [/SUP]
Affiliations
- PMID: 35035974
- PMCID: PMC8755926
- DOI: 10.1177/2050313X211069023
Abstract
Coronavirus disease 2019 (COVID-19) has affected over 200 million patients worldwide. COVID-19 is transmitted through respiratory droplets from patient to patient or by touching a surface that has been contaminated by an infected patient. Many COVID-19 patients have other comorbidities, such as end-stage renal disease. Currently, management of COVID-19 in patients with end-stage renal disease is unclear. Some studies have shown improvement in this population with the use of tocilizumab, a humanized interleukin-6 monoclonal antibody, in addition to the standard therapy as per guidelines published by the National Institutes of Health. In this case report, we present a patient case where the use of remdesivir, tocilizumab, and pulse-dose methylprednisolone significantly improved symptoms and inflammatory biomarkers associated with COVID-19 in a patient with end-stage renal disease.
Keywords: COVID-19; Critical care/emergency medicine; end-stage renal disease; infectious diseases; nephrology; remdesivir; steroids; tocilizumab.